先前接受parp抑制剂治疗的卵巢癌患者的维持性奥拉帕尼再挑战:患者报告的IIIB期OReO/engot-ov38试验结果

A. Redondo, P. Follana, G. Scambia, B. Asselain, F. Marmé, M. Mirza, M. E. Laudani, R. Mądry, R. Glasspool, B. You, M. J. Rubio-Pérez, C. Zamagni, A. El-Balat, A. Hardy-Bessard, A. Oaknin, G. Ronzino, B. Shaw, Hitomi Nakamura, D. Berton, E. Pujade-Lauraine
{"title":"先前接受parp抑制剂治疗的卵巢癌患者的维持性奥拉帕尼再挑战:患者报告的IIIB期OReO/engot-ov38试验结果","authors":"A. Redondo, P. Follana, G. Scambia, B. Asselain, F. Marmé, M. Mirza, M. E. Laudani, R. Mądry, R. Glasspool, B. You, M. J. Rubio-Pérez, C. Zamagni, A. El-Balat, A. Hardy-Bessard, A. Oaknin, G. Ronzino, B. Shaw, Hitomi Nakamura, D. Berton, E. Pujade-Lauraine","doi":"10.1136/ijgc-2022-igcs.27","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":312680,"journal":{"name":"Focused Plenary Abstracts","volume":"21 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"O025/#522 Maintenance olaparib rechallenge in patients with ovarian cancer previously treated with a parp inhibitor: patient-reported outcomes from the phase IIIB OReO/engot-ov38 trial\",\"authors\":\"A. Redondo, P. Follana, G. Scambia, B. Asselain, F. Marmé, M. Mirza, M. E. Laudani, R. Mądry, R. Glasspool, B. You, M. J. Rubio-Pérez, C. Zamagni, A. El-Balat, A. Hardy-Bessard, A. Oaknin, G. Ronzino, B. Shaw, Hitomi Nakamura, D. Berton, E. Pujade-Lauraine\",\"doi\":\"10.1136/ijgc-2022-igcs.27\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":312680,\"journal\":{\"name\":\"Focused Plenary Abstracts\",\"volume\":\"21 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Focused Plenary Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2022-igcs.27\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Focused Plenary Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2022-igcs.27","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
O025/#522 Maintenance olaparib rechallenge in patients with ovarian cancer previously treated with a parp inhibitor: patient-reported outcomes from the phase IIIB OReO/engot-ov38 trial
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信